#United States #Toronto #Alamar Biosciences #Tau Protein #AAIC 2025

Alamar Biosciences Breaks New Ground at AAIC 2025

Alamar Biosciences, a leader in targeted proteomics focused on early disease detection, has made significant strides in the field of neurodegenerative disease diagnosis. The company presented pioneering data regarding phosphorylated tau protein at the Alzheimer's Association International Conference (AAIC) 2025, held in Toronto from July 27-31. This notable event gathered global experts to discuss the latest breakthroughs in dementia research.

During the conference, Alamar showcased data from its innovative NULISA™ platform across more than 30 scientific sessions and poster presentations. This advanced platform offers unprecedented sensitivity and specificity in biomarker detection, which is crucial for the diagnosis and monitoring of neurodegenerative disorders such as Alzheimer’s disease. The revelation of robust clinical data on phosphorylated tau protein came as a highlight, underpinned by the analysis of 120 key proteins associated with central nervous system diseases. This achievement promises to enhance early detection capabilities and therapeutic monitoring for Alzheimer’s and related conditions.

Dr. Yuling Luo, the founder and CEO of Alamar Biosciences, expressed pride in the presentation before a prominent audience at AAIC, emphasizing the platform's power in delivering reliable results. The data presented include measurements of phosphorylated tau protein from individuals born in 1946, introducing new isoforms of the protein using the NULISAseq™ 120 CNS disease panel. Importantly, these findings indicate the exceptional ability of phosphorylated tau proteins to predict Alzheimer’s disease development several years before clinical diagnosis.

The presentation highlighted several key findings:

• - Correlation with Disease Progression: Analysis revealed a significant correlation between phosphorylated tau protein levels and PET imaging of amyloid and tau. This relationship presents a promising avenue for understanding Alzheimer’s disease progression.
• - Pathological Biomarkers: Utilizing the NULISAseq™ 120 panel, Alamar identified biomarkers that effectively detect neurodegenerative pathologies and comorbid conditions associated with Alzheimer’s disease through post-mortem confirmed patients.
• - Preclinical Studies: Alamar's preclinical data using mouse models further demonstrate the platform's utility in analyzing plasma and brain homogenate samples across various clinical Alzheimer’s models.

AAIC serves as the foremost global forum for the dementia research community, bringing together leading experts, scientists, and clinicians to share new discoveries and foster collaborations. The conference is vital for pushing the boundaries of effective diagnosis and therapies for Alzheimer’s disease. To view the complete list of presentations and posters featuring NULISA data, attendees were directed to the conference's official platform.

Alamar Biosciences, as a private life sciences company, remains committed to developing targeted proteomics solutions that facilitate early detection of diseases. Their proprietary NULISA platform and the ARGO HT system leverage the latest genomic insights, achieving detection sensitivity at the attomolar levels—significantly surpassing existing leading protein detection technologies on the market. For more information, visit alamarbio.com.